Maciej Krzakowski
Overview
Explore the profile of Maciej Krzakowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
5835
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Knetki-Wroblewska M, Wojas-Krawczyk K, Krawczyk P, Krzakowski M
Transl Lung Cancer Res
. 2025 Jan;
13(12):3718-3730.
PMID: 39830769
Immune checkpoint inhibitors (ICIs) have become an established treatment option for patients with advanced non-small cell lung cancer (NSCLC). However, the efficacy of single-agent immunotherapy as well as in combination...
2.
Zaborowska-Szmit M, Szmit S, Olszyna-Serementa M, Zajda K, Janowicz-Zebrowska A, Jaskiewicz P, et al.
Cardiooncology
. 2024 Nov;
10(1):79.
PMID: 39522050
Background: Venous thromboembolic events (VTE) are often diagnosed in ALK-positive lung cancer although it has not been demonstrated how their co-occurrence affects patients' survival. Methods: The study included patients with...
3.
Kowalski D, Zaborowska-Szmit M, Bryl M, Byszek A, Dziedzic D, Jaskiewicz P, et al.
Int J Mol Sci
. 2024 Nov;
25(21).
PMID: 39518907
Molecular testing is recommended in patients with metastatic non-small cell lung cancer (NSCLC), but the extent of its use in Poland is unknown. The aim of the POL-MOL study was...
4.
Piorek A, Pluzanski A, Knetki-Wroblewska M, Winiarczyk K, Tabor S, Kowalski D, et al.
Oncol Rev
. 2024 Oct;
18:1451247.
PMID: 39360235
A substantial portion of patients with advanced cancer cannot be cured, regardless of the therapeutic methods employed. Hence, rational palliative causal treatment becomes crucial. Representative studies specifically addressing the exclusive...
5.
Piorek A, Pluzanski A, Wisniewski P, Tabor S, Winiarczyk K, Knetki-Wroblewska M, et al.
Diseases
. 2024 Aug;
12(8).
PMID: 39195180
Pulmonary benign metastasizing leiomyoma (PBML) is a rare condition characterized by the spread of uterine leiomyomas to the lungs, typically observed in premenopausal women with a history of hysterectomy or...
6.
Svaton M, Knetki-Wroblewska M, Tabor S, Domecky P, Venclicek O, Krejci J, et al.
In Vivo
. 2024 Aug;
38(5):2434-2440.
PMID: 39187353
Background/aim: Cemiplimab in patients with non-small cell lung cancer (NSCLC) with PD-L1 (programmed death ligand type 1) expression ≥50% showed a significant improved overall survival (OS) with increasing expression of...
7.
Kulecka M, Czarnowski P, Balabas A, Turkot M, Kruczkowska-Tarantowicz K, Zeber-Lubecka N, et al.
Int J Mol Sci
. 2024 Aug;
25(15).
PMID: 39125593
The key association between gut dysbiosis and cancer is already known. Here, we used whole-genome shotgun sequencing (WGS) and gas chromatography/mass spectrometry (GC/MS) to conduct metagenomic and metabolomic analyses to...
8.
Macioch T, Krzakowski M, Golebiewska K, Dobek M, Warchalowska N, Niewada M
Discov Oncol
. 2024 Jul;
15(1):303.
PMID: 39048812
The efficacy of pembrolizumab in the treatment-naïve non-small-cell lung cancer (NSCLC) patients was proved in the KEYNOTE-024 randomized trial. The aim of this systematic literature review was to identify and...
9.
Kowalski D, Zaborowska-Szmit M, Szmit S, Jaskiewicz P, Krzakowski M
Transl Lung Cancer Res
. 2024 Jul;
13(6):1426-1431.
PMID: 38973950
No abstract available.
10.
Piorek A, Pluzanski A, Knetki-Wroblewska M, Winiarczyk K, Tabor S, Teterycz P, et al.
BMC Cancer
. 2024 Jun;
24(1):686.
PMID: 38840114
Objective: Primary tracheal tumors are very rare and their management is not definitely established. Due to its rarity, providing patient care in terms of optimal management poses a considerable challenge....